Crinetics Pharmaceuticals, Inc.

CRNX

Crinetics Pharmaceuticals, Inc.

CRNX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-17Shares Purchased (TTM):0Shares Sold (TTM):191,780

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:112,274,243Shares Outstanding:104,099,000Institutional Ownership Pct.:107.85%

Earnings Market Reaction:

Filing Date:2026-08-03Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	55	114	102	111	54	95	265	317	302	396	55	143
Restricted Cash	-	-	1	-	-	-	1	-	-	-	0	-
Restricted Cash Current	-	-	0	1	1	1	1	-	-	-	-	-
Short Term Investments	1,150	1,177	926	981	1,143	1,180	1,090	545	561	505	504	412
Accounts Receivable Net Current	12	6	1	-	-	-	0	-	-	-	-	-
Inventory Net	3	3	2	-	-	-	0	-	-	-	-	-
Prepaid Expense And Other Assets Current	23	22	18	28	20	16	21	15	12	16	16	21
Assets Current	1,244	1,322	1,048	1,121	1,217	1,291	1,375	878	875	917	574	576
Property Plant And Equipment Net	13	13	14	14	15	13	12	12	12	12	11	10
Derivative Assets	-	-	-	-	-	-	-	-	-	-	0	0
Operating Lease Right Of Use Asset	39	40	40	41	42	43	44	44	45	46	47	48
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	-	-	-	-	-	14	3	3	2	2	2	2
Prepaid Expense And Other Assets Noncurrent	25	25	22	18	15	-	3	-	-	-	-	-
Assets	1,322	1,401	1,126	1,196	1,290	1,361	1,435	937	936	978	635	642
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	42	37	42	34	38	32	21	18	24	29	23	22
Deferred Revenue Current	-	-	-	-	-	-	-	2	3	-	-	-
Deferred Revenue	-	-	-	2	2	2	2	-	-	2	2	2
Contract With Customer Liability Current	2	1	1	-	-	-	2	-	-	-	-	-
Operating Lease Liability Current	7	7	6	6	7	7	7	7	7	6	4	4
Liabilities Current	80	71	85	74	68	57	60	54	54	52	44	40
Operating Lease Liability Noncurrent	41	41	42	43	43	44	45	45	46	47	48	48
Deferred Revenue Noncurrent	-	-	-	4	4	4	5	5	4	5	5	5
Contract With Customer Liability Noncurrent	3	3	4	-	-	-	5	-	-	-	-	-
Other Liabilities Noncurrent	6	5	3	3	2	2	1	1	0	-	0	-
Liabilities	130	121	134	124	118	107	110	104	105	103	96	94
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stocks Including Additional Paid In Capital	2,862	2,828	2,408	2,365	2,335	2,301	2,276	1,702	1,626	1,595	1,192	1,142
Accumulated Other Comprehensive Income Loss Net Of…	-3	-1	2	2	2	2	1	2	-0	0	1	-1
Retained Earnings Accumulated Deficit	-1,666	-1,545	-1,417	-1,295	-1,165	-1,049	-952	-872	-795	-721	-654	-594
Common Stock Held In Trust	-	-	-	-	-0	-	-	-	-	-	-	-
Common Stock Shares Held In Employee Trust	-1	-1	-0	-0	-	-	0	-	-	-	-	-
Stockholders Equity	1,192	1,281	992	1,072	1,172	1,254	1,325	833	831	875	539	548
Liabilities And Stockholders Equity	1,322	1,401	1,126	1,196	1,290	1,361	1,435	937	936	978	635	642
Trading Securities Debt Amortized Cost	1,153	1,178	924	979	1,141	1,178	1,089	-	-	-	503	-
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	106	105	96	95	94	94	93	81	79	79	68	67
Shares Outstanding	106	105	96	95	94	94	93	81	79	79	68	32

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-18.26%	-15.61%	92.53%	-	-	-	-	-	-	-	-	-
2025	-6.70%	-8.38%	-5.23%	11.15%	64.67%	47.02%	4.76%	10.28%	22.28%	-18.68%	-6.26%	-15.94%
2024	-10.14%	-9.37%	10.00%	4.57%	0.02%	14.23%	0.15%	-9.58%	-31.44%	3.64%	-8.40%	-5.93%
2023	-	-	-	0.81%	71.91%	63.70%	10.91%	20.53%	25.95%	3.58%	0.49%	20.21%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	15.57	18.60	12.32	15.12	17.80	22.53	23.04	16.38	16.09	17.72	13.07	14.23
Quick Ratio	15.24	18.25	12.09	14.74	17.50	22.24	22.70	16.11	15.87	17.40	12.71	13.71
Working Capital	1.16B	1.25B	963.27M	1.05B	1.15B	1.23B	1.32B	824.03M	820.40M	865.46M	530.21M	535.30M
Leverage & Debt
Debt to Equity	0.11	0.09	0.14	0.12	0.10	0.09	0.08	0.13	0.13	0.12	0.18	0.17
Debt Ratio	0.10	0.09	0.12	0.10	0.09	0.08	0.08	0.11	0.11	0.11	0.15	0.15
Efficiency & Turnover
Asset Turnover TTM	0.03	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01
Days Sales Outstanding TTM	103.53	114.80	28.08	-	-	-	-	-	-	-	-	-
Receivables Turnover TTM	3.53	3.18	13.00	-	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-4.75	-4.77	-4.95	-4.49	-3.94	-3.53	-3.69	-3.47	-3.27	-3.26	-3.69	-3.51
Free Cash Flow Per Share TTM	-3.69	-4.03	-4.08	-2.85	-2.35	-2.90	-2.90	-2.57	-2.37	-2.55	-2.94	-2.94
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-1,302.52%	-3,020.32%	-6,714.77%	-31,130.16%	-30,392.17%	-49,569.74%	-32,613.47%	-29,525.22%	-20,068.38%	-12,571.38%	-5,547.17%	-4,394.45%
Net Profit Margin TTM	-1,189.88%	-2,747.18%	-6,046.22%	-27,563.32%	-26,568.53%	-43,191.05%	-28,720.69%	-26,747.83%	-18,667.15%	-11,928.27%	-5,345.85%	-4,223.27%
Growth Metrics
Net Revenue Growth (1Y)	2,928.45%	2,277.50%	640.71%	47.74%	0.51%	-61.50%	-74.11%	-78.00%	-71.35%	-53.93%	-15.28%	-7.52%
Net Income Growth (1Y)	35.63%	51.22%	55.93%	52.24%	43.05%	39.41%	39.10%	39.36%	40.59%	34.33%	30.88%	33.20%
EPS Growth (1Y)	20.51%	35.25%	33.93%	29.42%	20.50%	8.24%	-0.01%	-1.15%	-3.42%	0.17%	17.15%	26.07%
Valuation Metrics
P/E TTM	-7.87	-7.62	-9.41	-9.27	-7.29	-9.51	-13.84	-14.73	-13.69	-14.37	-9.63	-8.47
P/B TTM	3.31	2.95	4.41	3.66	2.30	2.49	3.12	4.91	4.26	3.87	3.83	3.08
P/S TTM	93.70	209.25	568.91	2,556.39	1,937.81	4,108.74	3,975.39	3,939.03	2,555.07	1,714.21	514.87	357.79
Market Cap	3.95B	3.78B	4.38B	3.92B	2.70B	3.12B	4.13B	4.09B	3.54B	3.38B	2.07B	1.69B
Enterprise Value	3.89B	3.67B	4.28B	3.81B	2.64B	3.03B	3.86B	3.77B	3.24B	2.99B	2.01B	1.55B
Calculated Values
Free Cash Flow TTM	-389.94M	-419.52M	-383.68M	-268.53M	-220.30M	-269.54M	-234.04M	-205.59M	-187.08M	-184.45M	-171.00M	-167.03M
Net Debt	-56.30M	-115.14M	-102.34M	-110.90M	-55.03M	-95.87M	-265.85M	-318.57M	-303.46M	-397.22M	-54.90M	-142.80M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-17Sale

Owner: Okey, Stephanie

Title: -

Shares: 6,900

Price/Share: $35.92

Value: $247,848.00

Shares Owned: 6,400

Relationship: Director

Ownership: Direct

2026-04-08Sale

Owner: Knight, Jeff E.

Title: Chief Dev. & Operating Officer

Shares: 85,163

Price/Share: $40.10

Value: $3,415,036.30

Shares Owned: 105,289

Relationship: Officer

Ownership: Direct

2026-03-16Sale

Owner: Struthers, Richard Scott

Title: President & CEO

Shares: 21,981

Price/Share: $37.44

Value: $822,968.64

Shares Owned: 404,778

Relationship: Director,Officer

Ownership: Direct

2026-03-16Sale

Owner: Knight, Jeff E.

Title: Chief Operating Officer

Shares: 9,911

Price/Share: $37.44

Value: $371,067.84

Shares Owned: 112,018

Relationship: Officer

Ownership: Direct

2026-03-16Sale

Owner: Betz, Stephen F.

Title: Chief Scientific Officer

Shares: 10,612

Price/Share: $37.44

Value: $397,313.28

Shares Owned: 137,101

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-17	Okey, Stephanie	Director	-	Direct	Sale	6,900	35.92	$247,848.00	6,400	4
2026-04-08	Knight, Jeff E.	Officer	Chief Dev. & Operating Officer	Direct	Sale	85,163	40.10	$3,415,036.30	105,289	4
2026-03-16	Struthers, Richard Scott	Director,Officer	President & CEO	Direct	Sale	21,981	37.44	$822,968.64	404,778	4
2026-03-16	Knight, Jeff E.	Officer	Chief Operating Officer	Direct	Sale	9,911	37.44	$371,067.84	112,018	4
2026-03-16	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	10,612	37.44	$397,313.28	137,101	4
2026-03-12	Vivaldi, Coelho Rogerio	Director	-	Direct	Sale	5,000	36.42	$182,100.00	16,300	4
2026-03-03	Schilke, Tobin	Officer	Chief Financial Officer	Direct	Sale	6,713	39.67	$266,304.71	78,121	4
2026-03-03	Okey, Stephanie	Director	-	Direct	Sale	3,000	39.67	$119,010.00	13,300	4
2026-01-05	Kalofonos, Isabel	Officer	Chief Commercial Officer	Direct	Sale	2,500	55.00	$137,500.00	834	4
2025-12-01	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	5,000	45.02	$225,100.00	66,837	4
2025-11-03	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	5,000	42.96	$214,800.00	66,270	4
2025-10-01	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	5,000	41.81	$209,050.00	66,270	4
2025-09-26	Fust, Matthew K	Director	-	Direct	Sale	16,000	44.75	$716,000.00	22,836	4
2025-09-26	Struthers, Richard Scott	Director,Officer	President & CEO	Indirect	Sale	4,000	45.00	$180,000.00	106,000	4
2025-09-02	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	5,000	32.10	$160,500.00	96,270	4
2025-08-22	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	30,000	30.43	$912,900.00	66,270	4
2025-08-20	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	6,492	29.18	$189,436.56	66,270	4
2025-06-12	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	97,483	32.23	$3,141,877.09	99,713	4
2025-03-19	Knight, Jeff E.	Officer	Chief Operating Officer	Direct	Sale	7,162	34.50	$247,089.00	87,491	4
2025-03-19	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	2,515	34.50	$86,767.50	72,233	4
2025-03-19	Struthers, Richard Scott	Director,Officer	President & CEO	Direct	Sale	17,338	34.50	$598,161.00	329,147	4
2025-03-19	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	5,770	34.50	$199,065.00	108,588	4
2025-02-03	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	5,000	39.07	$195,350.00	31,748	4
2025-01-03	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	15,000	52.09	$781,350.00	29,248	4
2024-12-02	Struthers, Richard Scott	Director,Officer	President & CEO	Indirect	Sale	10,000	57.57	$575,700.00	100,000	4
2024-11-22	Knight, Jeff E.	Officer	Chief Operating Officer	Direct	Sale	501	56.52	$28,316.52	51,653	4
2024-10-03	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	14,375	54.63	$785,306.25	28,507	4
2024-09-26	Wilson, Marc	Officer	CFO	Direct	Sale	25,000	51.11	$1,277,750.00	111,092	4
2024-09-10	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	1,035	51.50	$53,302.50	68,576	4
2024-08-26	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	53.19	$159,570.00	69,611	4
2024-08-12	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	47.68	$143,040.00	72,611	4
2024-07-25	Wilson, Marc	Officer	CFO	Direct	Sale	19,056	53.88	$1,026,737.28	111,092	4
2024-07-25	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	53.43	$160,290.00	75,611	4
2024-07-15	Wilson, Marc	Officer	CFO	Direct	Sale	25,000	55.00	$1,375,000.00	111,092	4
2024-07-15	Knight, Jeff E.	Officer	Chief Operating Officer	Direct	Sale	27,000	55.00	$1,485,000.00	51,653	4
2024-07-10	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	48.55	$145,650.00	78,611	4
2024-07-05	Hassard, James	Officer	Chief Commercial Officer	Direct	Sale	15,000	44.08	$661,200.00	29,259	4
2024-07-03	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	14,375	44.87	$645,006.25	28,507	4
2024-06-28	Wilson, Marc	Officer	CFO	Direct	Sale	32,129	43.61	$1,401,145.69	111,092	4
2024-06-26	Knight, Jeff E.	Officer	Chief Operating Officer	Direct	Sale	956	44.38	$42,427.28	52,580	4
2024-06-25	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	45.37	$136,110.00	80,643	4
2024-06-24	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	9,500	45.73	$434,435.00	27,786	4
2024-06-21	Hassard, James	Officer	Chief Commercial Officer	Direct	Sale	15,000	44.66	$669,900.00	29,259	4
2024-06-10	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	43.86	$131,580.00	83,643	4
2024-05-28	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	47.49	$142,470.00	86,643	4
2024-05-10	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	49.43	$148,290.00	89,643	4
2024-05-08	Struthers, Richard Scott	Director,Officer	President & CEO	Direct	Sale	107,448	49.40	$5,307,931.20	257,485	4
2024-04-15	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	14,375	44.47	$639,256.25	27,786	4
2024-04-04	Struthers, Richard Scott	Director,Officer	President & CEO	Direct	Sale	40,951	49.17	$2,013,560.67	237,835	4
2024-03-28	Okey, Stephanie	Director	-	Direct	Sale	17,500	46.38	$811,650.00	6,000	4
2024-03-22	Knight, Jeff E.	Officer	Chief Operating Officer	Direct	Sale	32,359	44.80	$1,449,683.20	52,580	4
2024-03-20	Fust, Matthew K	Director	-	Direct	Sale	60,000	44.06	$2,643,600.00	18,536	4
2024-03-20	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	15,089	44.29	$668,291.81	27,786	4
2024-03-19	Wilson, Marc	Officer	CFO	Direct	Sale	6,942	42.91	$297,881.22	110,630	4
2024-01-25	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	37.26	$111,780.00	73,298	4
2024-01-10	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	37.65	$112,950.00	76,298	4
2024-01-03	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	14,375	35.00	$503,125.00	5,911	4
2024-01-02	Wilson, Marc	Officer	CFO	Direct	Sale	10,000	35.47	$354,700.00	96,055	4
2023-12-26	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	35.89	$107,670.00	79,298	4
2023-12-21	Pizzuti, Dana	Officer	Chief Med and Dev Officer	Direct	Sale	9,583	34.57	$331,284.31	5,911	4
2023-12-11	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	32.87	$98,610.00	82,298	4
2023-11-27	Betz, Stephen F.	Officer	Chief Scientific Officer	Direct	Sale	3,000	31.84	$95,520.00	85,298	4
2023-11-03	Struthers, Richard Scott	Director,Officer	President & CEO	Direct	Sale	199,082	30.56	$6,083,945.92	135,522	4
2023-11-01	Wilson, Marc	Officer	CFO	Direct	Sale	10,000	28.75	$287,500.00	95,601	4
2023-10-17	Krasner, Alan Seth	Officer	Chief Medical Officer	Direct	Sale	7,000	30.00	$210,000.00	43,210	4
2023-07-13	Struthers, Richard Scott	Director,Officer	President & CEO	Indirect	Sale	14,157	20.35	$288,094.95	630,805	4
2023-06-20	Wilson, Marc	Officer	CFO	Direct	Sale	30,922	19.96	$617,203.12	95,158	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

107.85%

Inst. Shares: 112,274,243

Shares Outstanding: 104,099,000

2025-12-31

109.86%

Inst. Shares: 103,327,996

Shares Outstanding: 94,057,000

2025-09-30

106.47%

Inst. Shares: 100,311,788

Shares Outstanding: 94,215,000

2025-06-30

102.33%

Inst. Shares: 95,973,875

Shares Outstanding: 93,791,000

2025-03-31

100.37%

Inst. Shares: 93,448,585

Shares Outstanding: 93,102,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	112,274,243	104,099,000	107.85%
2025-12-31	103,327,996	94,057,000	109.86%
2025-09-30	100,311,788	94,215,000	106.47%
2025-06-30	95,973,875	93,791,000	102.33%
2025-03-31	93,448,585	93,102,000	100.37%
2024-12-31	90,062,544	80,783,000	111.49%
2024-09-30	75,637,577	80,091,000	94.44%
2024-06-30	73,894,487	79,008,000	93.53%
2024-03-31	71,075,367	72,289,000	98.32%
2023-12-31	62,739,051	58,071,000	108.04%
2023-09-30	62,562,378	56,808,000	110.13%
2023-06-30	49,689,897	54,275,000	91.55%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Crinetics Pharmaceuticals, Inc. (CRNX) — SEC Financial Statements & Analysis

Crinetics Pharmaceuticals, Inc. (CRNX) is a pharmaceutical preparations company, incorporated in DE. Crinetics Pharmaceuticals, Inc. trades on Nasdaq as: CRNX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Crinetics Pharmaceuticals, Inc. reported a 2928.45% year-over-year revenue growth, a Debt-to-Equity ratio of 0.11x, a Price-to-Sales (P/S) ratio of 93.70x (TTM), a Price-to-Book (P/B) ratio of 3.31x (TTM), at a market cap of $3.95B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 2928.45%
Debt To Equity: 0.11x
P/S TTM: 93.70x
P/B TTM: 3.31x
Market Cap: $3.95B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Crinetics Pharmaceuticals, Inc. in?

Crinetics Pharmaceuticals, Inc. (CRNX) operates in the Pharmaceutical Preparations industry.

What is CRNX's market cap?

Crinetics Pharmaceuticals, Inc. (CRNX) has a market capitalization of $3.95B as of 2026-06-30.

What exchange does CRNX trade on?

Crinetics Pharmaceuticals, Inc. (CRNX) trades on the Nasdaq.

Where is Crinetics Pharmaceuticals, Inc. incorporated?

Crinetics Pharmaceuticals, Inc. is incorporated in DE.